Mapping of drug-related problems among older adults conciliating medical and pharmaceutical approaches

Author(s):  
Marie-Laure Laroche ◽  
Thi Hong Van Ngo ◽  
Caroline Sirois ◽  
Amélie Daveluy ◽  
Michel Guillaumin ◽  
...  
2013 ◽  
Vol 61 (8) ◽  
pp. 1365-1368 ◽  
Author(s):  
Joseph T. Hanlon ◽  
Kenneth E. Schmader ◽  
Todd P. Semla

2020 ◽  
Vol 42 (4) ◽  
pp. 559-572.e14 ◽  
Author(s):  
Ana I. Plácido ◽  
Maria Teresa Herdeiro ◽  
Manuel Morgado ◽  
Adolfo Figueiras ◽  
Fátima Roque

Author(s):  
Benoit Cossette ◽  
Geneviève Ricard ◽  
Rolande Poirier ◽  
Suzanne Gosselin ◽  
Marie-France Langlois ◽  
...  

PLoS ONE ◽  
2020 ◽  
Vol 15 (7) ◽  
pp. e0236830
Author(s):  
Sirasa Ruangritchankul ◽  
Nancye M. Peel ◽  
Leila Shafiee Hanjani ◽  
Leonard C. Gray

Gerontology ◽  
2022 ◽  
pp. 1-10
Author(s):  
Akshaya Srikanth Bhagavathula ◽  
Wubshet Tesfaye ◽  
Kota Vidyasagar ◽  
Daniela Fialova

<b><i>Background and Aim:</i></b> Polypharmacy (concomitant use of 5–9 medicines) and hyperpolypharmacy (concomitant use of over 10 medicines) were observed to be more frequent in older adults (≥65 years) and associated with adverse outcomes. Their prevalence and risk in older patients with Parkinson’s disease (PD) remain unknown. We aimed to synthesize the extant evidence on the prevalence and risk of polypharmacy and hyperpolypharmacy in older adults with PD. <b><i>Methods:</i></b> A systematic literature search was performed in PubMed/MEDLINE, Scopus, and Embase databases to identify pertinent studies published from 2000 to July 2021. Observational studies reporting the prevalence and association with disease of polypharmacy/hyperpolypharmacy in older adults with PD were meta-analyzed. Pooled prevalence and odds ratio (OR) with 95% confidence intervals (CIs) were calculated. <b><i>Results:</i></b> Out of the total 499 studies identified, 6 fulfilled the inclusion criteria and comprised 7,171 participants. The overall prevalence of polypharmacy and hyperpolypharmacy was 40% (95% CI: 37–44) and 18% (95% CI: 13–23), respectively. A meta-analysis of 4 studies indicated a significant association between polypharmacy (OR: 1.94, 95% CI: 1.26–2.62; <i>p</i> &#x3c; 0.001) and PD. Hyperpolypharmacy was also strongly associated with PD (OR: 3.11, 95% CI: 2.08–4.14; <i>p</i> &#x3c; 0.001). <b><i>Conclusion:</i></b> Polypharmacy (40%) and hyperpolypharmacy (18%) are highly prevalent and eventually increase the risk of drug-related problems in older adults with PD. Therefore, interventions that ensure rational geriatric pharmacotherapy are of critical importance for the older population with neurogenerative disorders.


2018 ◽  
Vol 40 (2) ◽  
pp. 368-375 ◽  
Author(s):  
Jiadan Yang ◽  
Long Meng ◽  
Yu Liu ◽  
Liping Lv ◽  
Shusen Sun ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ana Isabel Plácido ◽  
Maria Teresa Herdeiro ◽  
João Lindo Simões ◽  
Odete Amaral ◽  
Adolfo Figueiras ◽  
...  

Abstract Background Polymedicated older patients are at greater risk of suffering from adverse events. For this reason, the detection of both inappropriate polypharmacy and polypharmacy-associated Drug-Related Problems (DRPs) are essential to improve the health and wellbeing of older adults and to reduce healthcare costs. This work aims to explore health professionals’ perceptions and opinions about polypharmacy and the handling of medicines by polymedicated older adults. Methods Thirteen focus groups with 94 health professionals (20 community pharmacists, 40 general practitioners and, 34 nurses) were conducted in primary healthcare centers of the center region of Portugal. Participants were asked to discuss their perceptions and beliefs concerning DRPs in polymedicated older adults. The sessions were audiotaped. After the transcription and coding of focus group sessions, a thematic analysis was done. Results The following four main themes emerged from the 13 focus group sessions: poor compliance and polypharmacy- A perpetuated vicious cycle, organization of the healthcare system, interaction and communication between the health professionals, and strategies to prevent inappropriate polypharmacy. Conclusions The lack of both an efficient network of information and Interaction and communication between Health professionals makes the detection and/ or prevention of polypharmacy in older adults difficult. The implementation of new models to manage and/or prevent polypharmacy based on health professional perception and beliefs is essential to prevent DRPs and improve compliance among older adults.


Sign in / Sign up

Export Citation Format

Share Document